Selenomethionine Suppress the Progression of Poorly Differentiated Thyroid
Cancer <i>via</i> LncRNA NONMMUT014201/miR-6963-5p/Srprb Pathway

Pan, Rongfang; Zhao, Junyu; Yao, Jinming; Gao, Yanyan; Liao, Lin

doi:10.2174/0113862073286006231228070738

Cited by 1 publication

(1 citation statement)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Presumably, in MTC-SK cells, the added selenium in the form of NASeLM can be converted into other selenium-containing forms (such as selenium-containing proteins) that only occur in thyroid cancer cells (such as iodothyronine deiodase or thioreduxin reductase) as described in a paper by Venture et al [ 20 ]. In their paper, they surveyed all scientific studies on selenium and thyroid diseases and were able to show that organic selenium-containing substances, in particular, as well as NASeLM, displayed a beneficial health effect on thyroid diseases and on poorly differentiated thyroid cancer [ 21 ]. Here, another possible mechanism of action that is pointed out is that seleno-methionine inhibits cell growth in a dose-dependent manner via the LncRNA-NONMMUT014201/miR-6963-5p/Srprb pathway.…”

Section: Discussionmentioning

confidence: 99%

The Influence of N-Acetyl-selenomethionine on Two RONS-Generating Cancer Cell Lines Compared to N-Acetyl-methionine

Greilberger,

Stiegler,

Greilberger

et al. 2024

Cells

View full text Add to dashboard Cite

N-acetyl-selenomethionine (NASeLM), a representative of the selenium compounds, failed to convince in clinical studies and cell cultures that it neither inhibits cancer growth nor has a chemoprotective effect. This study aims to find out whether NASeLM shows a growth-inhibiting property compared to the carrier substance N-Acetyl-L-methionine (NALM) on two different cancer cells, namely Jurkat cells and MTC-SK cells. Methods: Jurkat and MTC-SK cells were cultured in the absence or presence of varying concentrations (0–500 µg/mL) of NASeLM and NALM solutions. After 0, 24, 48, and 72 h, mitochondrial activity, cancer cell membrane CP levels, cell growth, and caspase-3 activity were assessed in aliquots of Jurkat and MTC-SK cells. Results: Both substances, NASeLM and NALM, were similarly able to inhibit cell growth and mitochondrial activity of Jurkat cells in a concentration-dependent and time-dependent manner up to 70%. Only the determination of caspase activity showed that only NASeLM was able to increase this to almost 40% compared to the control as well as the same lack of NALM. However, the experiments on MTC-SK cells showed a clear difference in favor of NASeLM compared to NALM. While NASeLM was able to reduce cell growth to up to 55%, the same amount of NALM was only at around 15%, which turned out to be highly significant (p < 0.001). The same could also be measured for the reduction in MTC-SK mitochondrial activity. Time dependence could also be recognized: the longer both substances, NASeLM and NALM, were incubated, the higher the effect on cell growth and mitochondrial activity, in favour of NASeLM. Only NASeLM was able to increase caspase-3 activity in MTC-SK cells: at 250 µg/mL NASeLM, caspase-3 activity increased significantly to 28% after 24 and 48 h compared to the control (14%) or the same NALM concentration (14%). After 72 h, this could still increase to 37%. A further increase in the NASeLM concentration did not result in higher caspase-3 activity. Conclusion: NASeLM could clearly increase caspase-3 activity in both cell types, Jurkat or MTC-SK cells, and thus induce cell death. NALM and NASeLM showed a reduction in cell growth and mitochondrial activity in both cell lines: While NALM and NASeLM showed almost identical measurements on Jurkat cells, NASeLM was much more effective on MTC-SK than the non-selenium-containing carrier, indicating that it has additional anti-chemoprotective effects.

show abstract

Section: Discussionmentioning

confidence: 99%